Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177911 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Eleftherios A Makris und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA. Hauptthemen laut MEDLINE: Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Neoplasms, Organoids, Mesothelioma, Malignant. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Eleftherios Makris’ NIH K12 award.
Abstract (Originalsprache)
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare malignancy for which cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is central to treatment in appropriately selected patients. Recurrence remains common even after complete macroscopic cytoreduction. Current HIPEC regimens are protocolized at the institutional and population levels but are not individualized using site-specific molecular or functional tumor biology. We performed a narrative review of clinical, genomic, epigenetic, immune, microenvironmental, and patient-derived organoid evidence relevant to DMPM, CRS/HIPEC, and treatment resistance. Recurrence is multifactorial, with plausible contributions from spatial, histologic, genomic, epigenetic, immune, stromal, and pharmacokinetic heterogeneity. Three primary reports provide direct DMPM organoid evidence, including preliminary demonstrations of patient-specific drug response and discordant responses among anatomically distinct implants. However, these platforms differ biologically, and predictive thresholds, analytical reproducibility, turnaround time, and microenvironmental modeling remain unvalidated. Multi-site organoid pharmacotyping integrated with molecular profiling is therefore a plausible strategy for studying HIPEC resistance. Translation requires a staged pathway encompassing analytical validity, blinded clinical validity, and clinical-utility testing. Precision HIPEC should presently be considered an investigational, validation-ready framework rather than a standard of care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Surgical Oncology, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA.
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC 27157, USA.
- Wake Forest Organoid Research Center, Winston-Salem, NC 27157, USA.
ORCID-Profile: Eleftherios A Makris
Förderung
- NCATS NIH HHS
- Eleftherios Makris’ NIH K12 award
Zitieren
APA
Makris, E. A., Ives, J. K., & Votanopoulos, K. (2026). Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177911
Vancouver
Makris EA, Ives JK, Votanopoulos K. Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177911
BibTeX
@article{Makris2026,
author = {Makris, Eleftherios A and Ives, James K and Votanopoulos, Konstantinos},
title = {Patient-Derived Organoid Models and Precision HIPEC in Diffuse Malignant Peritoneal Mesothelioma: Modeling Heterogeneity to Address Recurrence},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177911}
}
EUVIMED